The safety and efficacy of adding once‐daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aims: Evaluate the safety and efficacy of once‐daily insulin detemir initiated in routine clinical practice in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycaemic agents ( OHAs ). Methods: This large observational study was conducted in 10 countries. Adverse event data (including hypoglycaemia) and glycaemic control were recorded before and 24 weeks following insulin initiation while patients continued routine clinical management. Results: In this study, 17 374 patients (53% male) were included. Mean pre‐insulin values (±s.d.) were: age 62 ± 12 years; body mass index ( BMI ) 29.3 ± 5.4 kg/m 2 ; diabetes duration 10 ± 7 years; haemoglobin A1c ( HbA1c ) 8.9 ± 1.6%. During the study, 27 patients experienced serious adverse drug reaction, severe hypoglycaemic events or both; and there were 31 episodes of severe hypoglycaemia in 21 patients. After 24 weeks, HbA1c was 7.5 ± 1.2% (change of −1.3%; p < 0.001) and mean weight change was −0.6 kg (confidence interval −0.7, −0.5 kg, p < 0.001). Daily insulin dose increased from 13 ± 6 U (0.16 ± 0.09 U/kg) to 22 ± 16 U (0.27 ± 0. 17U /kg) by 24 weeks. Multivariate regression analysis identified several independent demographic and treatment predictors of end of study HbA1c . Conclusions: Addition of once‐daily insulin detemir to patients with type 2 diabetes mellitus on OHA therapy resulted in few adverse events, significant improvements in glycaemic control, small reductions in weight and low rates of hypoglycaemia. On the basis of this study, concerns about hypoglycaemia or weight gain should not preclude initiation of basal insulin analogues in patients with poor glycaemic control on OHAs .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Self-citationFrequency of Severe Hypoglycemia Requiring Emergency Treatment in Type 1 and Type 2 Diabetes
Leese, G. P., Wang, J., Broomhall, J., Kelly, P., Marsden, A., Morrison, W., Frier, B. M., Morris, A. D., & For the DARTS/MEMO Collaboration (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1176 · Cited by 559
Donnelly, L. A., Morris, A. D., Frier, B. M., Ellis, J. D., Donnan, P. T., Durrant, R., Band, M. M., Reekie, G., & Leese, G. P. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01501.x · Cited by 511
Hypoglycemia in Type 2 Diabetes
Zammitt, N. N., & Frier, B. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2948 · Cited by 435
Miller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., et al. (2010) · BMJ · doi:10.1136/bmj.b5444 · Cited by 429
Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes
Davies, M., Storms, F., Shutler, S., Bianchi-Biscay, M., Gomis, R., & for the AT.LANTUS Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1282 · Cited by 314
Hypoglycaemia in insulin‐treated Type 2 diabetes: frequency, symptoms and impaired awareness
Henderson, J. N., Allen, K. V., Deary, I. J., & Frier, B. M. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01072.x · Cited by 287
Cited by
Khunti, K., Alsifri, S., Aronson, R., Cigrovski Berković, M., Enters‐Weijnen, C., Forsén, T., Galstyan, G., Geelhoed‐Duijvestijn, P., Goldfracht, M., Gydesen, H., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12689 · Cited by 276
Insights into optimal basal insulin titration in type 2 diabetes: Results of a quantitative survey
Berard, L., Bonnemaire, M., Mical, M., & Edelman, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13064 · Cited by 69
“Biguanides 60 (39) 11 (14) 9 (10) 80 (25)”
Kumar, A., Franek, E., Wise, J., Niemeyer, M., Mersebach, H., & Simó, R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163350 · Cited by 38
Comparative effectiveness and safety of different basal insulins in a real-world setting
Ji, L., Zhang, P., Zhu, D., Lu, J., Guo, X., Wu, Y., Li, X., Ji, J., Jia, W., Yang, W., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12920 · Cited by 13
Self-citation
Metadata
- Authors
- Khunti, K., Caputo, S., Damci, T., Dzida, G. J., Ji, Q., Kaiser, M., Karnieli, E., Liebl, A., Ligthelm, R. J., Nazeri, A., Orozco‐Beltran, D., Pan, C., Ross, S. A., Svendsen, A. L., Vora, J., Yale, J. ‐., Meneghini, L. F., & on behalf of the SOLVE Study Group
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2012-08-30
- Volume
- 14
- Issue
- 12
- Pages
- 1129-1136
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2012125528
- Cited by
- 51
- References
- 12
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The safety and efficacy of adding once‐daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. https://app.cochat.ai/papers/10.1111/j.1463-1326.2012.01665.x
- The paper
- Khunti, K., Caputo, S., Damci, T., Dzida, G. J., Ji, Q., Kaiser, M., Karnieli, E., Liebl, A., Ligthelm, R. J., Nazeri, A., Orozco‐Beltran, D., Pan, C., Ross, S. A., Svendsen, A. L., Vora, J., Yale, J. ‐., Meneghini, L. F., & on behalf of the SOLVE Study Group. (2012). The safety and efficacy of adding once‐daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2012.01665.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.